PE20231842A1 - Coagonistas de los receptores de glp-1 y gip - Google Patents
Coagonistas de los receptores de glp-1 y gipInfo
- Publication number
- PE20231842A1 PE20231842A1 PE2023000027A PE2023000027A PE20231842A1 PE 20231842 A1 PE20231842 A1 PE 20231842A1 PE 2023000027 A PE2023000027 A PE 2023000027A PE 2023000027 A PE2023000027 A PE 2023000027A PE 20231842 A1 PE20231842 A1 PE 20231842A1
- Authority
- PE
- Peru
- Prior art keywords
- absent
- peptide
- glp
- substituent
- coagonists
- Prior art date
Links
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 2
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 title 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 title 1
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 abstract 3
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 abstract 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 150000001408 amides Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La invencion esta referida a un compuesto coagonista de molecula unica que comprende un peptido y un sustituyente; en donde el peptido tiene la secuencia de aminoacidos YX2EGTFTSDYSIYLX15X16X17AAX20X21FVX24WLLX28GGPX32X33X34X35X36X37X38X39 (SEQ ID NO.: 15), con una modificacion opcional de amida del extremo C-terminal; en donde X2 es Aib, X15 es D o E, X16 es E o K, X17 es Q o K, X20 es Aib, X21 es E o K, X24 es N o Q, X28 es A o E, X32 es S o ausente, X33 es S o ausente, X34 es G o ausente, X35 es A o ausente, X36 es P o ausente, X37 es P o ausente, X38 es P o ausente, X39 es S o ausente; y en donde el sustituyente se une al peptido mediante un residuo de Lisina (K) en la posicion 16, 17 o 21; y el sustituyente se selecciona del grupo que consiste en A, B, C, D, E, F o G, o una sal farmaceuticamente aceptable de este. Dichos compuestos son coagonistas del receptor del peptido 1 similar al glucagon (GLP-1) y del receptor del polipeptido insulinotropico dependiente de glucosa (GIP), y son de accion prolongada. Tambien se refiere a metodos para preparar dichos coagonistas de GLP-1/GIP y a una composicion farmaceutica que los comprende, siendo utiles en el tratamiento y/o la prevencion de la obesidad, la diabetes y/o enfermedades hepaticas
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055063P | 2020-07-22 | 2020-07-22 | |
| EP20192415 | 2020-08-24 | ||
| PCT/EP2021/070483 WO2022018185A1 (en) | 2020-07-22 | 2021-07-22 | Glp-1 and gip receptor co-agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231842A1 true PE20231842A1 (es) | 2023-11-21 |
Family
ID=77179984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023000027A PE20231842A1 (es) | 2020-07-22 | 2021-07-22 | Coagonistas de los receptores de glp-1 y gip |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230346961A1 (es) |
| EP (1) | EP4185606A1 (es) |
| JP (1) | JP2023534130A (es) |
| KR (1) | KR20230042019A (es) |
| CN (1) | CN116157414A (es) |
| AU (1) | AU2021313377A1 (es) |
| BR (1) | BR112023000229A2 (es) |
| CA (1) | CA3184723A1 (es) |
| CL (1) | CL2023000090A1 (es) |
| CO (1) | CO2023000125A2 (es) |
| IL (1) | IL299707A (es) |
| MX (1) | MX2023000403A (es) |
| PE (1) | PE20231842A1 (es) |
| TW (1) | TW202214679A (es) |
| WO (1) | WO2022018185A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119080887A (zh) * | 2022-07-13 | 2024-12-06 | 杭州中美华东制药有限公司 | Glp-1/gip双激动剂及其制备方法和用途 |
| WO2024165571A2 (en) | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025108381A1 (zh) * | 2023-11-22 | 2025-05-30 | 杭州中美华东制药有限公司 | Glp-1r/gipr双靶点激动剂在制备动物药中的用途 |
| WO2025125576A2 (en) | 2023-12-15 | 2025-06-19 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025133348A1 (en) | 2023-12-22 | 2025-06-26 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025149039A1 (zh) * | 2024-01-12 | 2025-07-17 | 杭州中美华东制药有限公司 | 长效glp-1/gip双激动剂的药物组合物 |
| WO2025196502A1 (en) | 2024-03-20 | 2025-09-25 | North Carolina Agricultural & Technical State University | Choline kinase inhibitors as a therapeutic treatment for obesity |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| EA020326B9 (ru) | 2008-06-17 | 2015-03-31 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения |
| EP2528618A4 (en) * | 2010-01-27 | 2015-05-27 | Univ Indiana Res & Tech Corp | GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS |
| AR084558A1 (es) * | 2010-12-22 | 2013-05-22 | Marcadia Biotech | Metodos para tratar trastornos metabolicos y obesidad con peptidos basados en glucagon activos para el receptor de peptido insulinotropico dependiente de glucosa (gip)/peptido-1 similar al glucagon (glp-1) |
| EP2718317B1 (en) | 2011-06-10 | 2018-11-14 | Beijing Hanmi Pharmaceutical Co., Ltd. | Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof |
| HUE064694T2 (hu) * | 2012-03-22 | 2024-04-28 | Novo Nordisk As | Továbbítószert tartalmazó készítmények és elõállításuk |
| AR090937A1 (es) | 2012-05-03 | 2014-12-17 | Zealand Pharma As | Compuestos agonista duales de gip-glp-1 y metodos para usarlos |
| PT2934568T (pt) | 2012-12-21 | 2018-01-04 | Sanofi Sa | Agonistas duplos de glp1/gip ou trigonais de glp1/gip/glucagina |
| AU2014261336B2 (en) * | 2013-05-02 | 2019-02-28 | Novo Nordisk A/S | Oral dosing of GLP-1 compounds |
| HUE057361T2 (hu) | 2013-05-28 | 2022-05-28 | Takeda Pharmaceuticals Co | Peptid vegyület |
| EP3033355A1 (en) | 2013-08-16 | 2016-06-22 | Medimmune Limited | Gip and glp-1 receptor dual-agonists for the treatment of diabetes |
| CA2929459C (en) | 2013-11-06 | 2022-05-03 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／ｇｉｐ受體促效劑 |
| TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| JP6657230B2 (ja) * | 2014-09-24 | 2020-03-04 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | インクレチン−インスリンコンジュゲート |
| JOP20200119A1 (ar) | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
| JP6920559B2 (ja) | 2018-07-23 | 2021-08-18 | イーライ リリー アンド カンパニー | Ｇｉｐ／ｇｌｐ１共アゴニスト化合物 |
-
2021
- 2021-07-22 TW TW110126884A patent/TW202214679A/zh unknown
- 2021-07-22 JP JP2022577749A patent/JP2023534130A/ja active Pending
- 2021-07-22 IL IL299707A patent/IL299707A/en unknown
- 2021-07-22 PE PE2023000027A patent/PE20231842A1/es unknown
- 2021-07-22 CA CA3184723A patent/CA3184723A1/en active Pending
- 2021-07-22 EP EP21749557.1A patent/EP4185606A1/en not_active Withdrawn
- 2021-07-22 CN CN202180060412.2A patent/CN116157414A/zh active Pending
- 2021-07-22 KR KR1020237002583A patent/KR20230042019A/ko active Pending
- 2021-07-22 WO PCT/EP2021/070483 patent/WO2022018185A1/en not_active Ceased
- 2021-07-22 MX MX2023000403A patent/MX2023000403A/es unknown
- 2021-07-22 AU AU2021313377A patent/AU2021313377A1/en active Pending
- 2021-07-22 US US18/016,947 patent/US20230346961A1/en active Pending
- 2021-07-22 BR BR112023000229A patent/BR112023000229A2/pt unknown
-
2023
- 2023-01-06 CO CONC2023/0000125A patent/CO2023000125A2/es unknown
- 2023-01-09 CL CL2023000090A patent/CL2023000090A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202214679A (zh) | 2022-04-16 |
| KR20230042019A (ko) | 2023-03-27 |
| CL2023000090A1 (es) | 2023-07-07 |
| WO2022018185A1 (en) | 2022-01-27 |
| CO2023000125A2 (es) | 2023-04-17 |
| EP4185606A1 (en) | 2023-05-31 |
| AU2021313377A1 (en) | 2023-02-02 |
| BR112023000229A2 (pt) | 2023-01-31 |
| IL299707A (en) | 2023-03-01 |
| CA3184723A1 (en) | 2022-01-27 |
| US20230346961A1 (en) | 2023-11-02 |
| JP2023534130A (ja) | 2023-08-08 |
| MX2023000403A (es) | 2023-02-02 |
| CN116157414A (zh) | 2023-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20231842A1 (es) | Coagonistas de los receptores de glp-1 y gip | |
| PE20231841A1 (es) | Coagonistas de los receptores glp-1 y gip adecuados para el suministro oral | |
| JP7211712B2 (ja) | グルカゴン受容体アゴニスト | |
| CN104945500B (zh) | 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症 | |
| JP6054861B2 (ja) | 新規のグルカゴン類似体 | |
| DK2694095T3 (en) | COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME | |
| RU2019122785A (ru) | Комбинации соединения на основе fgf21/агониста glp-1r с оптимизированным соотношением активности | |
| JP7280949B2 (ja) | タンパク質チロシン－チロシン類縁体およびそれを使用する方法 | |
| DK2864350T3 (en) | ANALOGUE OF GLUCAGON EXPRESSING GIP RECEPTOR ACTIVITY | |
| JP2025093970A (ja) | インクレチン類似体およびその使用 | |
| JP2016512213A5 (es) | ||
| RU2006120079A (ru) | Производные глюкагоноподобного пептида-1 (glp-1) | |
| RU2010101232A (ru) | Производное инсулинотропного пептида, содержащее модифицированную n-концевую аминокислоту | |
| PL2070946T3 (pl) | Wynalazek dotyczący GLP-1 i eksendyny | |
| JP2012512903A5 (es) | ||
| CN103080128B (zh) | Glp-1类似物的反相hplc纯化 | |
| JP2004509079A5 (es) | ||
| US20250188115A1 (en) | Process for preparing a glucagon-like peptide | |
| CN104470948A (zh) | Gip-glp-1双激动剂化合物及方法 | |
| NZ768446A (en) | Novel glp-1 analogues | |
| JP2017502024A5 (es) | ||
| US7811989B2 (en) | Peptide YY analogs | |
| WO2016131893A1 (en) | Incretin fusion polypeptides | |
| CN101155828A (zh) | Gip类似物和具有可选择性质的杂合多肽 | |
| PH12022552911A1 (en) | Long-acting glp-1 and glucagon receptor dual agonist |